Medipharm Labs Corp
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, develops, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based p… Read more
Medipharm Labs Corp (MEDIF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.004x
Based on the latest financial reports, Medipharm Labs Corp (MEDIF) has a cash flow conversion efficiency ratio of -0.004x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-158.00K) by net assets ($37.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medipharm Labs Corp - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Medipharm Labs Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Medipharm Labs Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medipharm Labs Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Groupe CRIT SA
PA:CEN
|
0.031x |
|
First Bancshares Inc. (Bellevue OH)
PINK:FIBH
|
0.005x |
|
Arogo Capital Acquisition Corp
NASDAQ:AOGO
|
-0.004x |
|
Tien Liang BioTech Co., Ltd.
TWO:4127
|
0.021x |
|
Xander International
TWO:6118
|
0.103x |
|
Eclipse Metals Ltd
AU:EPM
|
-0.064x |
|
Ram Technology Co. Ltd
KQ:171010
|
-0.006x |
|
SCHROD.BSC SOC.IMP.LS-01
F:783
|
N/A |
Annual Cash Flow Conversion Efficiency for Medipharm Labs Corp (2016–2024)
The table below shows the annual cash flow conversion efficiency of Medipharm Labs Corp from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $43.18 Million | $-4.86 Million | -0.113x | +51.65% |
| 2023-12-31 | $53.01 Million | $-12.34 Million | -0.233x | +18.87% |
| 2022-12-31 | $56.01 Million | $-16.07 Million | -0.287x | -80.55% |
| 2021-12-31 | $83.15 Million | $-13.21 Million | -0.159x | +67.01% |
| 2020-12-31 | $78.41 Million | $-37.77 Million | -0.482x | -151.09% |
| 2019-12-31 | $131.23 Million | $-25.18 Million | -0.192x | +99.26% |
| 2018-12-31 | $427.08K | $-11.11 Million | -26.021x | -6370.05% |
| 2017-12-31 | $400.00K | $166.00K | 0.415x | +263.49% |
| 2016-12-31 | $215.46K | $-54.69K | -0.254x | -- |